← Oncology Approval Tracker

FDA DECISION ·

Enzalutamide tablets

enzalutamide · Sandoz

First generic approvalFirst genericProstate cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

First generic of Xtandi tablets for castration-resistant prostate cancer, metastatic castration-sensitive disease or nonmetastatic castration-sensitive disease with high-risk biochemical recurrence.

LAMPGEN ANALYSIS

Why it matters

FDA’s first-generic listing applies to the tablet presentation. Each prostate cancer setting carries distinct staging and treatment-history criteria.

What research teams should watch

Check tablet sourcing and formulary status and document the disease setting. FDA approval alone does not establish a product's launch date.

PRIMARY RECORDS

Sources